Clear, source-led research guides to the compounds listed for laboratory research.
Updated October 2026
Selank is a synthetic tuftsin-related peptide. This guide separates its limited clinical literature from broader claims about mood, focus and everyday use.
Semax is a synthetic ACTH-related peptide studied in neurological research. Published patient studies should not be confused with evidence for general focus or memory enhancement.
DSIP means delta-sleep-inducing peptide. Its name reflects a research history, not a promise: small human sleep studies have produced limited and mixed findings.
Dihexa is an experimental angiotensin-IV-derived compound. Its evidence is preclinical, and an influential mechanism paper has been retracted.
Thymosin alpha-1 is a thymic peptide with an indication-specific clinical literature. Research on immune signalling is not a general claim of immune enhancement.
VIP stands for vasoactive intestinal peptide, a naturally occurring signalling peptide. Its diverse biological roles do not establish benefits from a research product.
Glutathione is an endogenous tripeptide studied in redox biology. Oral supplementation studies do not validate a pre-filled research pen or another delivery route.
KPV is the lysine–proline–valine tripeptide associated with alpha-MSH research. Its cited intestinal-inflammation evidence comes from cells and mice, not a human treatment trial.
SNAP-8 is associated with acetyl octapeptide-3 in cosmetic research. Evidence from a multi-ingredient microneedle patch cannot establish the peptide’s isolated effect.
Matrixyl is a trade name, not a sufficiently precise chemical identity on its own. This guide explains why the ingredient and formulation studied must be identified first.
Cagrilintide is a long-acting amylin analogue investigated in clinical research. A trial material and an online research listing are not interchangeable.
This listing combines retatrutide and cagrilintide. Separate trials of the components do not establish the effectiveness, compatibility or safety of this exact blend.
AOD-9604 is a modified growth-hormone fragment investigated in metabolic research. It should not be equated with full growth hormone or an unspecified fragment product.
Fragment 176–191 refers to a growth-hormone-derived fragment. Exact sequence matters: evidence for AOD-9604 is not automatically evidence for this material.
5-Amino-1MQ is a small-molecule NNMT inhibitor, not a peptide. The cited metabolic evidence is preclinical rather than proof of human outcomes.
SLU-PP-332 is a synthetic small molecule studied through estrogen-related receptors in mice. The phrase “exercise mimetic” describes an experimental concept, not a human benefit.
IGF-1 LR3 is a modified IGF-I analogue investigated in experimental systems. It differs from native IGF-I, especially in interactions with binding proteins.
This guide covers the No-DAC CJC-1295 and ipamorelin blend. Human research on long-acting CJC-1295 with DAC is not evidence for this exact combination.
GLOW is a named multi-ingredient research blend. This guide distinguishes supplier-described composition from the evidence for its individual components.
KLOW is a named multi-ingredient research blend. This guide distinguishes supplier-described composition from the evidence for its individual components.
Wolverine (BPC-157 + TB-500) is a named multi-ingredient research blend. This guide distinguishes supplier-described composition from the evidence for its individual components.
Latest guides
Updated August 2026
A source-led guide to the reproductive-axis regulator, the human IVF and neuroimaging studies, safety, and regulatory status.
A source-led guide to the mitochondrial-derived peptide, the AMPK pathway, the metabolic and exercise evidence, safety, and regulatory status.
A source-led guide to the copper tripeptide, the published hair-follicle and dermal papilla evidence, safety, and regulatory status.
A source-led guide to the melanocortin agonist, the RECONNECT Phase 3 trials, the Vyleesi approval, safety, and regulatory status.
A source-led guide to the GHRH analogue, the published human pharmacology studies, safety observations, and regulatory status.
A source-led guide to the selective growth hormone secretagogue, the human studies, safety observations, and regulatory status.
A source-led guide to the GHRH analogue, the Phase 3 trials, the Egrifta approval, safety observations, and regulatory status.
A source-led guide to the natural copper tripeptide, the skin and wound-healing evidence, safety observations, and regulatory status.
A source-led guide to its GLP-1 mechanism, the STEP, SELECT, and SUSTAIN trials, safety observations, and regulatory status.
A source-led guide to its dual-agonist mechanism, the SURPASS and SURMOUNT trials, safety observations, and regulatory status.
A source-led guide to its mechanism, clinical trials, safety observations, and regulatory status in the UAE and abroad.
Updated September 2026
A source-led head-to-head guide: trial evidence, the ongoing Phase 3 direct comparison, safety, and regulatory status.
A source-led laboratory guide: step-by-step reconstitution technique, dosage maths with the calculator, and storage and hygiene rules.
A source-led guide to what a Certificate of Analysis contains: purity and identity numbers, laboratory accreditation, and the red flags to check.
A source-led guide: synthesis and purification costs, research-grade vs pharmaceutical-grade standards, approval costs, and the cold chain.
A source-led guide: what lab analyses of online-purchased products actually found, official warning signs, and practical checks you can run.
A careful look at official sources: the EDE's role, the public drug directory, personal-import rules — and what those sources do not address.
The gastric pentadecapeptide: proposed mechanisms, the consistent preclinical literature, and the human evidence gap.
The difference between TB-500 and thymosin beta-4, actin regulation and cell migration, and what actually applies to humans.
The coenzyme at the heart of ageing research: sirtuins, age-related decline, and what human trials have found.
The pineal tetrapeptide: telomerase research, the Khavinson studies, and why human evidence remains thin.
SURPASS-2 and SURMOUNT-5: the two published head-to-head trials, the mechanistic difference, and side effects.